AIM ImmunoTech CEO buys 22,000 shares at $0.221

AIM ImmunoTech Inc. (AIM) reported that CEO & President Thomas K. Equels purchased 22,000 shares of its Common Stock on September 15, 2026 in a purchase described as an open market or private transaction at $0.221 per share.

Rhea-AI Filing Summary

AIM ImmunoTech Inc. (AIM) reported that CEO & President Thomas K. Equels purchased 22,000 shares of its Common Stock on September 15, 2026 in a purchase described as an open market or private transaction at $0.221 per share. Following this buy, he directly owns 91,822 shares of AIM Common Stock. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Net Buyer: 22,000 shares

Net Buy 1 txn

Insider Equels Thomas K

Role CEO & President

Bought 22,000 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	22,000	$0.221	$5K

Holdings After Transaction: Common Stock — 91,822 shares (Direct)

Key Figures

Shares purchased: 22,000 shares Purchase price per share: $0.221 per share Shares owned after transaction: 91,822 shares

3 metrics

Shares purchased 22,000 shares Common Stock bought by CEO on September 15, 2026

Purchase price per share $0.221 per share Price paid for AIM ImmunoTech Common Stock on September 15, 2026

Shares owned after transaction 91,822 shares Direct AIM ImmunoTech Common Stock holdings of CEO after the purchase

Key Terms

Common Stock, open market or private transaction, Rule 10b5-1, directly owns

4 terms

Common Stock financial

"purchased 22,000 shares of its Common Stock on September 15, 2026"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open market or private transaction financial

"purchase described as an open market or private transaction at $0.221"

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is reported for this transaction"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

directly owns financial

"Following this buy, he directly owns 91,822 shares of AIM Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AIM ImmunoTech (AIM) disclose in this Form 4?

The filing reports that CEO & President Thomas K. Equels purchased 22,000 shares of AIM ImmunoTech Common Stock on September 15, 2026 in an open market or private transaction.

At what price did the AIM ImmunoTech (AIM) CEO buy shares?

Thomas K. Equels bought 22,000 shares of AIM ImmunoTech Common Stock at $0.221 per share on September 15, 2026, as disclosed in the Form 4.

How many AIM (AIM ImmunoTech) shares does the CEO hold after this transaction?

After the reported purchase, Thomas K. Equels directly holds 91,822 shares of AIM ImmunoTech Common Stock, according to the Form 4 disclosure.

Was the AIM ImmunoTech (AIM) CEO’s stock purchase under a Rule 10b5-1 plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not checked, so this 22,000‑share purchase was not reported as being made under a Rule 10b5-1 trading plan.

What type of security did the AIM (AIM ImmunoTech) insider acquire?

Thomas K. Equels acquired Common Stock of AIM ImmunoTech, totaling 22,000 shares, through a purchase in an open market or private transaction on September 15, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 09:15 AM Accepted by SEC EDGAR 09/16/2026 - 09:15 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Equels Thomas K

(Last) (First) (Middle)

2117 SOUTHWEST HIGHWAY 484

(Street)

OCALA FLORIDA 34473

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AIM ImmunoTech Inc. [ AIM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		P		22,000	A	$0.221	91,822	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Thomas K Equels	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)